Cargando…

Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study

Metabolic syndrome (MS) involves pathophysiological alterations that might compromise zinc status. The aim of this study was to evaluate zinc status biomarkers and their associations with cardiometabolic factors in patients with MS. Our case control study included 88 patients with MS and 37 controls...

Descripción completa

Detalles Bibliográficos
Autores principales: Freitas, Erika P. S., Cunha, Aline T. O., Aquino, Sephora L. S., Pedrosa, Lucia F. C., Lima, Severina C. V. C., Lima, Josivan G., Almeida, Maria G., Sena-Evangelista, Karine C. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331606/
https://www.ncbi.nlm.nih.gov/pubmed/28241426
http://dx.doi.org/10.3390/nu9020175
_version_ 1782511412381220864
author Freitas, Erika P. S.
Cunha, Aline T. O.
Aquino, Sephora L. S.
Pedrosa, Lucia F. C.
Lima, Severina C. V. C.
Lima, Josivan G.
Almeida, Maria G.
Sena-Evangelista, Karine C. M.
author_facet Freitas, Erika P. S.
Cunha, Aline T. O.
Aquino, Sephora L. S.
Pedrosa, Lucia F. C.
Lima, Severina C. V. C.
Lima, Josivan G.
Almeida, Maria G.
Sena-Evangelista, Karine C. M.
author_sort Freitas, Erika P. S.
collection PubMed
description Metabolic syndrome (MS) involves pathophysiological alterations that might compromise zinc status. The aim of this study was to evaluate zinc status biomarkers and their associations with cardiometabolic factors in patients with MS. Our case control study included 88 patients with MS and 37 controls. We performed clinical and anthropometric assessments and obtained lipid, glycemic, and inflammatory profiles. We also evaluated zinc intake, plasma zinc, erythrocyte zinc, and 24-h urinary zinc excretion. The average zinc intake was significantly lower in the MS group (p < 0.001). Regression models indicated no significant differences in plasma zinc concentration (all p > 0.05) between the two groups. We found significantly higher erythrocyte zinc concentration in the MS group (p < 0.001) independent from co-variable adjustments. Twenty-four hour urinary zinc excretion was significantly higher in the MS group (p = 0.008), and adjustments for age and sex explained 21% of the difference (R(2) = 0.21, p < 0.001). There were significant associations between zincuria and fasting blood glucose concentration (r = 0.479), waist circumference (r = 0.253), triglyceride concentration (r = 0.360), glycated hemoglobin concentration (r = 0.250), homeostatic model assessment—insulin resistance (r = 0.223), and high-sensitivity C-reactive protein concentration (r = 0.427) (all p < 0.05) in the MS group. Patients with MS had alterations in zinc metabolism mainly characterized by an increase in erythrocyte zinc and higher zincuria.
format Online
Article
Text
id pubmed-5331606
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53316062017-03-13 Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study Freitas, Erika P. S. Cunha, Aline T. O. Aquino, Sephora L. S. Pedrosa, Lucia F. C. Lima, Severina C. V. C. Lima, Josivan G. Almeida, Maria G. Sena-Evangelista, Karine C. M. Nutrients Article Metabolic syndrome (MS) involves pathophysiological alterations that might compromise zinc status. The aim of this study was to evaluate zinc status biomarkers and their associations with cardiometabolic factors in patients with MS. Our case control study included 88 patients with MS and 37 controls. We performed clinical and anthropometric assessments and obtained lipid, glycemic, and inflammatory profiles. We also evaluated zinc intake, plasma zinc, erythrocyte zinc, and 24-h urinary zinc excretion. The average zinc intake was significantly lower in the MS group (p < 0.001). Regression models indicated no significant differences in plasma zinc concentration (all p > 0.05) between the two groups. We found significantly higher erythrocyte zinc concentration in the MS group (p < 0.001) independent from co-variable adjustments. Twenty-four hour urinary zinc excretion was significantly higher in the MS group (p = 0.008), and adjustments for age and sex explained 21% of the difference (R(2) = 0.21, p < 0.001). There were significant associations between zincuria and fasting blood glucose concentration (r = 0.479), waist circumference (r = 0.253), triglyceride concentration (r = 0.360), glycated hemoglobin concentration (r = 0.250), homeostatic model assessment—insulin resistance (r = 0.223), and high-sensitivity C-reactive protein concentration (r = 0.427) (all p < 0.05) in the MS group. Patients with MS had alterations in zinc metabolism mainly characterized by an increase in erythrocyte zinc and higher zincuria. MDPI 2017-02-22 /pmc/articles/PMC5331606/ /pubmed/28241426 http://dx.doi.org/10.3390/nu9020175 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Freitas, Erika P. S.
Cunha, Aline T. O.
Aquino, Sephora L. S.
Pedrosa, Lucia F. C.
Lima, Severina C. V. C.
Lima, Josivan G.
Almeida, Maria G.
Sena-Evangelista, Karine C. M.
Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study
title Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study
title_full Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study
title_fullStr Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study
title_full_unstemmed Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study
title_short Zinc Status Biomarkers and Cardiometabolic Risk Factors in Metabolic Syndrome: A Case Control Study
title_sort zinc status biomarkers and cardiometabolic risk factors in metabolic syndrome: a case control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331606/
https://www.ncbi.nlm.nih.gov/pubmed/28241426
http://dx.doi.org/10.3390/nu9020175
work_keys_str_mv AT freitaserikaps zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy
AT cunhaalineto zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy
AT aquinosephorals zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy
AT pedrosaluciafc zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy
AT limaseverinacvc zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy
AT limajosivang zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy
AT almeidamariag zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy
AT senaevangelistakarinecm zincstatusbiomarkersandcardiometabolicriskfactorsinmetabolicsyndromeacasecontrolstudy